Post-FDA Evidence Needed To Inform Coverage Decisions – McClellan
This article was originally published in The Gray Sheet
Executive Summary
Generating comparative effectiveness data is most realistic after FDA approval, but improved mechanisms are needed, according to CMS Administrator Mark McClellan